Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR

被引:21
作者
Huezo, H
Vilenchik, M
Rosen, N
Chiosis, G
机构
[1] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
来源
CHEMISTRY & BIOLOGY | 2003年 / 10卷 / 07期
关键词
D O I
10.1016/S1074-5521(03)00144-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overexpression of the transmembrane tyrosine kinases Her2 and EGFR is associated with aggressive malignancies, and several therapeutic strategies targeting the two receptors are now in various stages of clinical development. Most of the known agents block the activation or inhibit the activity of the kinases; however, a more significant therapeutic outcome may result from degrading these oncoproteins. Here, we report the development of a microtiter cell-based assay that sensitively detects cellular levels of Her2 and EGFR. The assay is useful in identifying small molecules that alter cellular levels of these kinases and in quantifying their effect. The method gives results comparable to Western blot, but it is faster, less labor intensive, and amenable to high throughput.
引用
收藏
页码:629 / 634
页数:6
相关论文
共 22 条
[1]   A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells [J].
Chiosis, G ;
Timaul, MN ;
Lucas, B ;
Munster, PN ;
Zheng, FF ;
Sepp-Lorenzino, L ;
Rosen, N .
CHEMISTRY & BIOLOGY, 2001, 8 (03) :289-299
[2]   Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase [J].
Chiosis, G ;
Lucas, B ;
Shtil, A ;
Huezo, H ;
Rosen, N .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (11) :3555-3564
[3]   Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy [J].
Citri, A ;
Alroy, I ;
Lavi, S ;
Rubin, C ;
Xu, WP ;
Grammatikakis, N ;
Patterson, C ;
Neckers, L ;
Fry, DW ;
Yarden, Y .
EMBO JOURNAL, 2002, 21 (10) :2407-2417
[4]   Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor [J].
Fry, DW ;
Bridges, AJ ;
Denny, WA ;
Doherty, A ;
Greis, KD ;
Hicks, JL ;
Hook, KE ;
Keller, PR ;
Leopold, WR ;
Loo, JA ;
McNamara, DJ ;
Nelson, JM ;
Sherwood, V ;
Smaill, JB ;
Trumpp-Kallmeyer, S ;
Dobrusin, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :12022-12027
[5]   PREVALENCE OF ABERRANT EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN CANCERS [J].
GULLICK, WJ .
BRITISH MEDICAL BULLETIN, 1991, 47 (01) :87-98
[6]   EXPRESSION OF THE NEU PROTOONCOGENE IN THE MAMMARY EPITHELIUM OF TRANSGENIC MICE INDUCES METASTATIC DISEASE [J].
GUY, CT ;
WEBSTER, MA ;
SCHALLER, M ;
PARSONS, TJ ;
CARDIFF, RD ;
MULLER, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (22) :10578-10582
[7]   Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins [J].
Marcu, MG ;
Schulte, TW ;
Neckers, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (03) :242-248
[8]   The EGF receptor family as targets for cancer therapy [J].
Mendelsohn, J ;
Baselga, J .
ONCOGENE, 2000, 19 (56) :6550-6565
[9]   SINGLE-STEP INDUCTION OF MAMMARY ADENOCARCINOMA IN TRANSGENIC MICE BEARING THE ACTIVATED C-NEU ONCOGENE [J].
MULLER, WJ ;
SINN, E ;
PATTENGALE, PK ;
WALLACE, R ;
LEDER, P .
CELL, 1988, 54 (01) :105-115
[10]   Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity [J].
Neckers, L ;
Schulte, TW ;
Mimnaugh, E .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (04) :361-373